Sanofi

Referencias

  1. Nicholas Hall Benchmarking the world of OTC 22/04/2021
  2. Prospectos aprobados por ANMAT: Dulcolax perlas Disp. N° 7594/14, Dulcolax gotas Disp. N° 6976/14, Dulcolax grageas Disp. N° 7260/14.
  3. Susanne Kienzle-Horn, Jean-Michel Vix, Chris Schuijt, Hubertus Peil, Chris C. Jordan & Michael A. Kamm (2007) Comparison of bisacodyl and sodium picosulphate in the treatment of chronic constipation, Current Medical Research and Opinion, 23:4, 691-699
  4. Bove A, Bellini M, Battaglia E, et al. Consensus statement AIGO/SICCR diagnosis and treatment of chronic constipation and obstructed defecation (part II: treatment). World J Gastroenterol. 2012;18(36):4994-5013.
  5. Friedrich C, Richter E, Trommeshauer D, et al. Absence of excretion of the active moiety of bisacodyl and sodium picosulfate unto human breast milk: an open label, parallel group, multiple-dose study in healthy lactating women. Drug Metab Pharmacokinet 2011;26 (5):458-64.
  6. Clinical Overview Bisacodyl. 2011; Kamm, M.A et. Al. Oral Bisacodyl is effective and well-tolerated in patients with chronic constipation. Clin.Gastreonterol.Hepatol. 2011; 9(7):577-583
  7. Wald A. Constipation in the primary care setting: current concepts and misconceptions. Am J Med. 2006 Sep;119(9):736-9. Review.
  8. Kim DH, Hyung SH, et al. The role of intestinal bacteria in the transformation of sodium picosulfate. Jpn J Pharmacol. 1992 May ;59(1): 1-5
  9. Brand Performance Tracking 18/19
  10. Kamm MA, et. Al Gastroenterol Hepatol 2011;9:577-83.